Literature DB >> 19387600

[Liver transplantation: indications and results].

C P Strassburg1, M P Manns.   

Abstract

After around 64,000 transplantations in Europe since 1988 liver transplantation has emerged as a standard treatment option for otherwise incurable chronic liver diseases. Cirrhosis of different etiologies represents the most frequent transplant indication. Overall survival in this group amounts to 72% after 5 years, and 62% after 10 years. In Germany, the main indications include alcoholic liver cirrhosis, tumors with increasing numbers in recent years, as well as viral diseases leading to cirrhosis. Since December 2006 the priority for liver transplantation is determined by the model for end stage liver disease (MELD) and not by the length of waiting time. MELD is a statistical model based on serum creatinine, serum bilirubin and coagulation, which describes the probability of 3-month mortality of a potential transplant candidate. Not all liver diseases are adequately represented by MELD necessitating the additional use of a defined number of standard exceptions that have been last updated in 2008. As a consequence of these developments indications, selection of recipients and the management of the waiting list have seen profound change.

Entities:  

Mesh:

Year:  2009        PMID: 19387600     DOI: 10.1007/s00108-008-2268-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  33 in total

1.  Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis.

Authors:  Jens J W Tischendorf; Peter N Meier; Christian P Strassburg; Jürgen Klempnauer; Hartmut Hecker; Michael P Manns; Martin Krüger
Journal:  Scand J Gastroenterol       Date:  2006-10       Impact factor: 2.423

2.  Impact of MELD on short-term and long-term outcome following liver transplantation: a European perspective.

Authors:  Evi Nagler; Hans Van Vlierberghe; Isabelle Colle; Roberto Troisi; Bernard de Hemptinne
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-08       Impact factor: 2.566

3.  Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival?

Authors:  Gerd R Silberhumer; Hubert Hetz; Susanne Rasoul-Rockenschaub; Markus Peck-Radosavljevic; Thomas Soliman; Rudolf Steininger; Ferdinand Muehlbacher; Gabriela A Berlakovich
Journal:  Transpl Int       Date:  2006-04       Impact factor: 3.782

Review 4.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

5.  Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation.

Authors:  Gabriele I Kirchner; Kinan Rifai; Tobias Cantz; Bjoern Nashan; Christoph Terkamp; Thomas Becker; Christian Strassburg; Hannelore Barg-Hock; Siegfried Wagner; Rainer Lück; Juergen Klempnauer; Michael P Manns
Journal:  Liver Transpl       Date:  2006-08       Impact factor: 5.799

6.  Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation.

Authors:  Jens Rosenau; Nazanin Hooman; Johannes Hadem; Kinan Rifai; Matthias J Bahr; Gunnar Philipp; Hans L Tillmann; Juergen Klempnauer; Christian P Strassburg; Michael P Manns
Journal:  Liver Transpl       Date:  2007-03       Impact factor: 5.799

Review 7.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

Review 8.  Management of hepatitis B in liver transplantation patients.

Authors:  Didier Samuel
Journal:  Semin Liver Dis       Date:  2004       Impact factor: 6.115

9.  Impact of the MELD score on waiting time and disease severity in liver transplantation in United States veterans.

Authors:  Jawad Ahmad; Kathy K Downey; Mohamed Akoad; Thomas V Cacciarelli
Journal:  Liver Transpl       Date:  2007-11       Impact factor: 5.799

10.  Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

Authors:  Marina Berenguer; Martín Prieto; Fernando San Juan; José M Rayón; Fernando Martinez; Domingo Carrasco; Angel Moya; Francisco Orbis; José Mir; Joaquín Berenguer
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

View more
  11 in total

1.  [Allocation systems in transplantation medicine: Advantages and disadvantages].

Authors:  J Gottlieb; W Gwinner; C P Strassburg
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

2.  [Treatment of autoimmune liver diseases. Autoimmune hepatitis and primary sclerosing cholangitis].

Authors:  C P Strassburg; M P Manns
Journal:  Internist (Berl)       Date:  2011-12       Impact factor: 0.743

Review 3.  HCC-Associated Liver Transplantation - Where Are the Limits and What Are the New Regulations?

Authors:  Christian P Strassburg
Journal:  Visc Med       Date:  2016-06-20

4.  [Diagnostics and therapy of hepatitis].

Authors:  C P Strassburg; M Cornberg
Journal:  Internist (Berl)       Date:  2009-12       Impact factor: 0.743

Review 5.  [Pulmonary complications of liver cirrhosis: hepatopulmonary syndrome, portopulmonary hypertension and hepatic hydrothorax].

Authors:  M Halank; C P Strassburg; M M Hoeper
Journal:  Internist (Berl)       Date:  2010-03       Impact factor: 0.743

Review 6.  [Patient selection and indications for liver transplantation].

Authors:  C P Strassburg
Journal:  Chirurg       Date:  2013-05       Impact factor: 0.955

Review 7.  [Hepatic steatosis : Differential diagnostics and current aspects].

Authors:  A Canbay; G Gerken; L P Bechmann
Journal:  Internist (Berl)       Date:  2016-09       Impact factor: 0.743

8.  Hepatic encephalopathy before and neurological complications after liver transplantation have no impact on the employment status 1 year after transplantation.

Authors:  Henning Pflugrad; Anita B Tryc; Annemarie Goldbecker; Christian P Strassburg; Hannelore Barg-Hock; Jürgen Klempnauer; Karin Weissenborn
Journal:  World J Hepatol       Date:  2017-04-08

9.  [Intensive therapy after solid organ transplantation].

Authors:  C Lichtenstern; M Müller; J Schmidt; K Mayer; M A Weigand
Journal:  Anaesthesist       Date:  2010-12       Impact factor: 1.041

10.  The current state and future prospects of chronic hepatitis C virus infection treatment.

Authors:  Christopher Moore; Josh Levitsky
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.